NEW: We've expanded Stock Detail, Screener, and Maps with new data

Stock Detail, Screener:
3, 5, 10-Year Performance
EV/EBITDA, EV/Sales
Dividend Growth (1, 3, 5 Years)
EPS & Sales Growth (3 Years)

Maps:
All from Screener plus:
ROA, ROE, ROIC
Quick & Current Ratios
LT Debt and Debt to Equity Ratios
Gross, Operating, and Net Margins

Last Close
Jun 24 12:35PM ET
14.72
Dollar change
+0.04
Percentage change
0.27
%
IndexRUT P/E9.96 EPS (ttm)1.48 Insider Own5.98% Shs Outstand12.22M Perf Week1.73%
Market Cap180.61M Forward P/E12.87 EPS next Y1.14 Insider Trans0.00% Shs Float11.54M Perf Month4.10%
Enterprise Value182.37M PEG- EPS next Q0.18 Inst Own87.16% Short Float0.43% Perf Quarter8.45%
Income18.27M P/S3.81 EPS this Y-6.60% Inst Trans-1.50% Short Ratio1.93 Perf Half Y15.10%
Sales47.44M P/B0.61 EPS next Y-16.31% ROA5.59% Short Interest0.05M Perf YTD17.20%
Book/sh23.95 P/C6.06 EPS next 5Y- ROE6.38% 52W High16.23 -9.28% Perf Year7.57%
Cash/sh2.43 P/FCF6.77 EPS past 3/5Y-18.76% -10.11% ROIC5.64% 52W Low11.99 22.78% Perf 3Y-3.18%
Dividend Est.- EV/EBITDA5.09 Sales past 3/5Y-6.20% 8.36% Gross Margin92.12% Volatility2.40% 1.46% Perf 5Y37.49%
Dividend TTM- EV/Sales3.84 EPS Y/Y TTM54.41% Oper. Margin60.17% ATR (14)0.38 Perf 10Y65.97%
Dividend Ex-DateApr 24, 2025 Quick Ratio11.30 Sales Y/Y TTM18.18% Profit Margin38.52% RSI (14)58.83 Recom1.00
Dividend Gr. 3/5Y- - Current Ratio11.30 EPS Q/Q439.74% SMA202.64% Beta0.17 Target Price18.00
Payout0.00% Debt/Eq0.11 Sales Q/Q1.55% SMA503.51% Rel Volume0.07 Prev Close14.68
Employees24 LT Debt/Eq0.11 EarningsMay 15 AMC SMA2009.78% Avg Volume25.76K Price14.72
IPOSep 22, 1999 Option/ShortNo / Yes EPS/Sales Surpr.126.49% - Trades Volume907 Change0.27%
May-15-25 04:30PM
May-09-25 07:30AM
Apr-10-25 04:15PM
Mar-20-25 01:45PM
Mar-19-25 09:20PM
09:10PM Loading…
09:10PM
Mar-13-25 07:30AM
Feb-07-25 11:00AM
Jan-06-25 07:35AM
Nov-14-24 04:15PM
Oct-17-24 04:15PM
Aug-15-24 08:15AM
Jul-17-24 04:15PM
Jul-08-24 05:00PM
May-19-24 08:08AM
10:54PM Loading…
May-15-24 10:54PM
04:05PM
Mar-23-24 05:33AM
Mar-21-24 01:53PM
07:00AM
Jan-23-24 04:05PM
Nov-09-23 07:30AM
Nov-06-23 04:05PM
Oct-30-23 08:00AM
Oct-18-23 08:00AM
Oct-11-23 08:00AM
Oct-03-23 04:05PM
Sep-28-23 06:34PM
Sep-26-23 04:07PM
Aug-17-23 09:00AM
04:05PM Loading…
Aug-09-23 04:05PM
Aug-08-23 08:00AM
Jul-27-23 05:43PM
Jul-17-23 04:05PM
Jun-28-23 04:05PM
May-11-23 09:00AM
07:00AM
May-02-23 04:36PM
Apr-03-23 07:30AM
Mar-31-23 08:00AM
SWK Holdings Corp. engages in financial and asset management in the field of pharmaceuticals. The company offers capital and investments in life science companies, institutions, and inventors. It operates through the Finance Receivables and Pharmaceutical Development segments. The Finance Receivables segment is a healthcare capital provider which offers customized financing solutions to a broad range of life science companies, institutions, and investors. It is primarily focused on monetizing cash flow streams derived from commercial-stage products and related intellectual property through royalty purchases and financings, as well as through the creation of synthetic revenue interests in commercialized products. The Pharmaceutical Development segment strategy is to utilize the Peptelligence platform to create a wholly-owned portfolio of milestone and royalty income by out-licensing the technology. The company was founded in July 1996 and is headquartered in Dallas, TX.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Staggs Joe David JRPRESIDENTApr 15 '25Option Exercise11.2233,750378,525149,623Apr 17 04:34 PM